OsteoDex is DexTech's lead candidate for the treatment of castration-resistant prostate cancer and has completed clinical phase 2. In October 2023, the Company filed a patent application with the EPO (European patent office, application No. 23203437.1). The application concerned GMP (Good Manufacturing Practice) manufacturing of OsteoDex. The application has now been approved, and a patent has been granted. The patent is of great importance for the continued clinical development of OsteoDex and future market exclusivity. The patent is valid until 2045 and is very positive for the Company's partnership/out-licensing talks.

"This is gratifying news as OsteoDex's patent protection is a key factor in our partnership discussions. Licensees have a requirement for a longer period of market exclusivity after registration, which we meet with the patent by far," says CEO Anders R Holmberg

For more information about DexTech, please contact:

Gösta Lundgren - CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 19, 2025.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The lead candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech's goal is to out-license each drug candidate no later than after completion of the phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.